Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05404945
Title Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Virginia

Hodgkin's lymphoma


Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine

Brentuximab vedotin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Virginia Recruiting Charlottesville Virginia 22911 United States Details
*Shaded cells indicate that there was no data available from for the field